ReviewHuman vaccines & immunotherapeutics2021
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection.
Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Encephalitic alphavirus infection induces long-term humoral and cell-mediated responses in seropositive participants from Panama.PLoS neglected tropical diseases · 2026Article
- A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Widespread SARS-CoV-2 Transmission Despite Limited Reported Cases and Clinical Disease: Exploring the Role of Pre-Existing Humoral Immunity to SARS-CoV-2 in Eastern Sierra Leone.Immunity, inflammation and disease · 2026Article
- Antibody engineering for SFTS treatment: frontier progress and translational challenges.Frontiers in microbiology · 2026Review
- An influenza HA mRNA-LNP vaccine induces potent responses in newborn nonhuman primates that enhance protection from challenge.NPJ vaccines · 2025Article
- Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS-CoV-2 Variants.Clinical and translational science · 2025Review
- Review
- Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies.Microbiology spectrum · 2025Article
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.EBioMedicine · 2025Article
- Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection.Antibodies (Basel, Switzerland) · 2024Review
- NIAID/SMB Workshop on Multiscale Modeling of Infectious and Immune-Mediated Diseases.Bulletin of mathematical biology · 2024Article
- Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection.The journal of allergy and clinical immunology. Global · 2024Article
- Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.Frontiers in immunology · 2024Review
- Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.The Journal of infectious diseases · 2023Article
- Modulating antibody effector functions by Fc glycoengineering.Biotechnology advances · 2023Review
- Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2.JCI insight · 2023Article
- Complement contributes to antibody-mediated protection against repeated SHIV challenge.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antibodies can provide antiviral protection through neutralization and recruitment of innate effector functions through the Fc domain. While neutralization has long been appreciated for its role in antibody-mediated protection, a growing body of work indicates that the antibody Fc domain also significantly contributes to antiviral protection. Recruitment of innate immune cells such as natural killer cells, neutrophils, monocytes, macrophages, dendritic cells and the complement system by antibodies can lead to direct restriction of viral infection as well as promoting long-term antiviral immunity. Monoclonal antibody therapeutics against viruses are increasingly incorporating Fc-enhancing features to take advantage of the Fc domain, uncovering a surprising breadth of mechanisms through which antibodies can control viral infection. Here, we review the recent advances in our understanding of antibody-mediated innate immune effector functions in protection from viral infection and review the current approaches and challenges to effectively leverage innate immune cells via antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.